Editor-in-Chief & Deputy Editor 2019-2021





Deputy Editor:



Sponsors & Partners

Acta Gastroenterologica Belgica is supported by grants from its major sponsors


Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma







Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies









Coeliac disease in patients with type 1 diabetes mellitus and auto-immune thyroid disorders

Price: €10,00

The paper aims to review the prevalence and natural history of coeliac disease in patients with type 1A diabetes mellitus and autoimmune thyroid disorders. These diseases share a similar genetic background. In diabetic children and adults, the prevalence of (mostly asymptomatic) coeliac disease varies form 0.97 to 6.4%. Diabetes is usually diagnosed first. Screening in relatives may also be positive. Recurrent hypoglycaemia in diabetic subjects (indirectly) suggest the development of coeliac sprue. Thyroid disorders (thyroiditis and Graves’ disease) are also usual in coeliac disease. A common etiopathogenic mechanism for the association CD / diabetes / thyroid disorders, with gluten as the driving antigen, was postulated. Thus, screening program for coeliac disease are recommended in individuals with type 1A diabetes and/or auto-immune thyroid conditions, as well as in their first-degree relatives. [Product Details...]

Digestive submucosal masses : endoscopic evaluation

Price: €10,00

No abstract available [Product Details...]

Epidemiology of coeliac disease

Price: €10,00

In this article we review recent worldwide epidemiological data of coeliac disease (CD). An emphasis is made on adult figures as there is reduction of infants cases that is counterbalanced by the increase of CD in older children or adults. We review data from Europe, USA, South America, Australia, Asia and Africa. Studies in mixed population and in patients undergoing endoscopy are also mentioned. The prevalence of the disease varies between 1/100-500 in different continents. It is possible that the low incidence of CD in some regions is due to the decrease of the prevalence of classic form of the disease. [Product Details...]

Laparoscopic surgery for cancer : Are we ready ?

Price: €10,00

Following feasibility studies more and more large prospective reports even randomised trials document the treatment of digestive cancer using a laparoscopic approach. While the spectre of port-site recurrences, once so alarming has faded, it has become a challenge for laparoscopic surgeons to provide long-term followup. There is good class II and III evidence that staging laparoscopy (SL) has a value for oesophageal, gastric, pancreatic and hepatobiliary cancer as well as for intra-abdominal lymphomas since it adds to primary staging and often alters the clinical stage of the disease and hence the management of the individual patient. For minimally invasive oesophagectomy and gastric cancer surgery several series have demonstrated shorter perioperative morbidity and hospital stay however at present most studies report smaller numbers of selected patients and long term follow up is rare. The laparoscopic resection of pancreatic malignancies is not reported to be feasible, safe or potentially beneficial for the patient while the curative resection of suspected early gallbladder cancer is a poor indication. Nevertheless laparoscopy is documented to be safe and applicable for small malignant liver lesions and the Lacy trial was significantly in favour of laparoscopy-assisted colectomy, predominantly for stage III disease. Bearing in mind that in many fields of digestive cancer surgery, laparoscopy should still be conducted as part of a trial, it is safe to say that “we are ready” for this revolution to arise [Product Details...]

Long term protection after hepatitis A and B vaccination : an update

Price: €10,00

No abstract available. [Product Details...]

Postexposure management of hepatitis A, B or C : Treatment, postexposure prophylaxis and recommendations

Price: €10,00

Although there is no consensus on the best management of acute hepatitis C or on optimal strategy of follow-up after potential contamination, certain guidelines can nevertheless be proposed for the care of these patients in practice. It is now recommended that acute hepatitis C be treated by interferon monotherapy in the presence of a C viremia, detectable by polymerase chain reaction, and an elevation of the transaminases. The earlier the treatment is started after appearance of symptoms, the more effective it is. Management of a potentially contaminated individual consists of screening for the C virus as early as the fifteenth day after the potentially contaminating act and, in the case of virus transmission, starting interferon treatment as soon as elevation of the transaminases appears. No special precautions are to be taken by the person potentially contaminated for avoiding possible secondary C virus transmission during the follow-up period. In the case of acute hepatitis B, antiviral treatment should not be started, in view of the high percentage of spontaneous recoveries and the potentially negative effect of treatment on the chances of spontaneous recovery. Post-exposure prophylaxis by antihepatitis B immunoglobin injections and/or vaccination should be considered after evaluation of the hepatitis B surface antigen status of the source and of the vaccination and vaccine-response status of the exposed person. The classic scheme for selecting the most appropriate postexposure prophylaxis is reminded. In post-exposure prophylaxis for hepatitis A virus, although there have been no studies comparing the effectiveness of vaccination with that of immunoglobin injections, it is at present proposed to provide only vaccination. The target groups eligible for postexposure prophylaxis are evoked. [Product Details...]

Vaccination for viral hepatitis in industrial health

Price: €10,00

No abstract available. [Product Details...]

  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»

Display #  
Results 1 - 7 of 7